Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

More Good News for Amarin Corporation plc (ADR) (AMRN): GlaxoSmithKline plc (ADR) (GSK)

Page 1 of 2

Last year, a number of drugs received FDA approval. The drug authority has rolled out one approval after another, maybe to compensate for the patent cliff most large pharmaceuticals are facing. These approvals have a significant impact on single drug companies, such as Amarin Corporation plc (ADR) (NASDAQ:AMRN). The company’s stock has traded as high as $19.50 on positive expectations from its star drug Vascepa. Small biopharmaceuticals with approved candidates are an ideal target for big pharmaceuticals. This is because buying a company with an already approved drug allows them to evade the risk of R&D and also avoid investor speculation on approvals.

Amarin Corporation plc (ADR) (NASDAQ:AMRN)If we take into account the patent cliff, one would consider Amarin Corporation plc (ADR) (NASDAQ:AMRN) an ideal takeover target. Sadly for Amarin investors this eventuality has still not transpired due to an inherent difficulty in valuing Amarin. A lack of NCE classification is the primary reason for this as the the lack of such a classification increases the uncertainty for any potential acquirers. One would assume that even if it doesn’t get the NCE classification, a target price can be calculated on the basis of 3 year exclusivity. I believe this has still not happened because the executive management of Amarin Corporation plc (ADR) (NASDAQ:AMRN) doesn’t want a penny less than Vascepa’s true potential.


Due to these issues Amarin Corporation plc (ADR) (NASDAQ:AMRN) has decided to commercialize its drug and has already launched Vascepa in the United States. The most recent quarterly results and the conference call that followed gave investors more insight into Vascepa’s commercialization efforts. A major obstacle for in-house commercialization especially without support from an established partner is a lack of trained sales persons. Amarin has been lucky in this regard because a number of major drugs, such as Lipitor, are facing expiring patents leading to huge sales force layoffs.  According to company disclosures, 275 sales representatives have been trained and are already in the field. I think the commercialization efforts for Vascepa have been a success. The IMS data shows that Vascepa is selling better than GlaxoSmithKline plc (ADR) (NYSE:GSK)’s Lovaza at the same point in time.

Quarterly results

The company has once again easily beaten the street’s earnings estimates. The street was expecting Amarin Corporation plc (ADR) (NASDAQ:AMRN) to report an EPS of $-0.28, but the company reported a net loss of only $10.6 million or $0.07, comprehensively beating estimates. More importantly the results indicate that the cash position of Amarin has significantly improved with the company ending the quarter with cash and equivalents of $260.2 million. The total outflows during the quarter were $55.4 million. This includes a significant $12.1 million payout to the shareholders of Laxdale and $16 million to suppliers to build up an inventory level for Vascepa’s commercial launch. The company has spent $12.1 million more on SG&A expenses to prepare for the commercial launch of Vascepa.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!